Key takeaways
These excerpts come from the original article. Read the full sections below for context.
- An M protein does not by itself establish active multiple myeloma. MGUS, smoldering myeloma, and active disease are distinguished using marrow findings, protein studies, imaging, and organ assessment. Hypercalcemia, renal impairment, anemia, and bone lesions must be attributable to the plasma-cell disorder when used as defining features. Certain biomarkers can also establish active disease before obvious organ damage occurs. IMWG diagnostic criteria for multiple myeloma
- A falling M protein or free light-chain concentration may indicate response, but formal assessment depends on the applicable criteria and other findings. Complete response and measurable residual disease negativity do not automatically establish cure or authorize a patient to stop treatment. A marrow-based result has limitations related to sampling, sensitivity, timing, and disease outside the sampled site.
- Provide marrow and FISH results, trends in monoclonal protein and free light chains, kidney function, bone imaging, and the full treatment history before travel. Ask what the receiving team expects an in-person visit to resolve. Fracture risk, dialysis, or recent infection may affect the journey, and a hospital accepting a referral cannot replace the current doctor's travel assessment.
Quick answer
Multiple myeloma treatment is usually a sequence of decisions rather than a single procedure. The team needs to control abnormal plasma cells, address bone and kidney problems, and plan subsequent treatment and monitoring. At diagnosis, the most useful questions are whether the criteria for treatment have been met, whether an organ problem needs urgent attention, and which initial strategy fits the person's condition.
Full guide
Multiple myeloma treatment is usually a sequence of decisions rather than a single procedure. The team needs to control abnormal plasma cells, address bone and kidney problems, and plan subsequent treatment and monitoring. At diagnosis, the most useful questions are whether the criteria for treatment have been met, whether an organ problem needs urgent attention, and which initial strategy fits the person's condition.
Some people first present with back pain or a fracture. Others are investigated for anemia, kidney impairment, or a monoclonal protein. These routes to diagnosis can create different immediate priorities. Another patient's drug list may therefore provide little guidance until the treating doctor explains which problem is being addressed in your case. NCI multiple myeloma treatment PDQ
Establish the plasma-cell diagnosis before choosing its management
An M protein does not by itself establish active multiple myeloma. MGUS, smoldering myeloma, and active disease are distinguished using marrow findings, protein studies, imaging, and organ assessment. Hypercalcemia, renal impairment, anemia, and bone lesions must be attributable to the plasma-cell disorder when used as defining features. Certain biomarkers can also establish active disease before obvious organ damage occurs. IMWG diagnostic criteria for multiple myeloma
Consequently, an absence of pain or a currently normal creatinine cannot independently settle whether treatment is needed. Conversely, anemia or chronic kidney disease may have another cause in someone who also has a monoclonal protein. Ask the hematologist to identify the criterion that has been met and the report that supports it. This turns an unfamiliar label into a decision you can examine.
Smoldering disease also requires an updated discussion. In November 2025, the FDA approved subcutaneous daratumumab and hyaluronidase for adults with high-risk smoldering multiple myeloma. The indication does not cover every risk category. Chinese authorization and practical access require separate verification, so the US action should inform a question for the receiving team rather than become a promise of treatment in China. FDA high-risk smoldering myeloma approval
Urgent organ problems may set the initial timetable
Myeloma-related kidney impairment can require prompt reduction of the harmful light-chain burden and management of contributing dehydration, infection, or other factors. The assessment can include creatinine, estimated filtration, free light chains, and urine studies. Treatment sometimes needs to begin after essential evaluation while more detailed reports are still pending. Fluid intake and intravenous fluids must take the person's heart and kidney condition into account. IMWG recommendations on myeloma-related renal impairment
New leg weakness, altered sensation, difficulty walking, or loss of bladder or bowel control with back pain requires urgent assessment for spinal or nerve compression. Marked drowsiness, confusion, severe thirst, or persistent vomiting can also indicate a problem that should not wait for a routine consultation. A person preparing to travel to China should obtain local emergency care if these changes develop rather than wait for the international appointment.
Bone pain is not always adequately managed by increasing pain medication. Imaging may reveal a fracture or instability requiring orthopedic, spinal, or radiation assessment. Avoid forceful manipulation or loading an unassessed painful spine. Preserving safe movement and function belongs alongside systemic therapy in the treatment plan. NICE recommendations for myeloma care
Choose initial therapy as part of a complete strategy
Initial treatment commonly combines medicines with different mechanisms, such as a proteasome inhibitor, an immunomodulatory drug, an anti-CD38 antibody, and a corticosteroid. The particular agents, doses, and schedule depend on kidney function, neuropathy, infection risk, frailty, and other clinical features. A greater number of medicines does not automatically make a regimen more suitable for every person. EHA–EMN 2025 myeloma guideline
The initial discussion should connect induction to response assessment, stem-cell collection when appropriate, possible autologous transplantation, and maintenance. Cytogenetic risk can influence those decisions, but a high-risk result should not erase the need to consider what a person can safely tolerate. For an older or frail patient, a sustainable regimen that limits avoidable toxicity can be central to effective care.
PERSEUS, for example, evaluated a daratumumab-containing strategy in transplant-eligible newly diagnosed patients. Its comparison involved induction and consolidation as well as different maintenance components, with improved disease control in the experimental strategy. Ask how closely your situation resembles the studied population and which parts of the strategy are being proposed. Reducing the trial to a statement that one additional injection is always better misses important context. PERSEUS randomized study
Discuss practical concerns before the first prescription. Existing numbness, difficult transport, uncontrolled diabetes, recurrent infection, or an inability to manage a complex tablet schedule can change the plan. These are not secondary details to mention only after a complication; they help the team choose a treatment you can actually complete.
Discuss autologous transplantation early without making age the sole rule
Autologous stem-cell transplantation generally uses the patient's own blood-forming cells to support recovery after high-dose treatment. It is not the same as obtaining donor marrow to replace every myeloma cell. Assessment considers function, comorbidities, organ health, treatment response, and personal preferences, rather than a birthday or one creatinine value alone.
Even if transplantation is not immediately chosen, stem-cell collection may need early planning. The duration and nature of preceding treatment can affect collection strategy, and an unplanned transfer between hospitals can disrupt it. Ask whether cells should be collected now, whether they can be stored, and how the timing relates to the current induction course.
DETERMINATION informs the role of transplantation within a particular initial treatment pathway, including a progression-free benefit and a different burden of adverse effects. It cannot decide the tradeoff for every patient. The doctor should explain how the study relates to your fitness, disease risk, available alternatives, and willingness to undergo an intensive treatment period. DETERMINATION randomized study
Separate the logistics of collection, storage, high-dose treatment, reinfusion, and recovery. Treating these as one appointment underestimates the time and support required. If future fertility is important, raise it before relevant therapy so there is an opportunity to discuss preservation and medication-related reproductive risks.
Response and maintenance require continued interpretation
A falling M protein or free light-chain concentration may indicate response, but formal assessment depends on the applicable criteria and other findings. Complete response and measurable residual disease negativity do not automatically establish cure or authorize a patient to stop treatment. A marrow-based result has limitations related to sampling, sensitivity, timing, and disease outside the sampled site.
Maintenance choices depend on the initial strategy, transplantation, disease risk, and tolerance. Some patients need prolonged therapy with ongoing review of blood counts, infection, neuropathy, and daily function. If treatment persistently prevents sleep, eating, or mobility, report the problem. There may be ways to adjust supportive care or the regimen rather than accepting every symptom as unavoidable.
Use a medication schedule that separates anticancer tablets, steroid days, infection prevention, and other supportive medicines. Intermittent regimens are particularly easy to misunderstand after discharge. Obtain instructions for missed doses, vomiting, or newly prescribed medicines and do not rely solely on memory from a previous hospital stay.
Relapse decisions depend on what has already been used
For a later treatment decision, the team needs to know previous drug exposure, which therapies the disease resisted, the duration of benefit, and serious prior toxicity. A rapid decline in kidney function, worsening bone disease, or extramedullary disease may change urgency. Clinical trials, bispecific antibodies, CAR-T therapy, and other regimens each have conditions for use and should not be ordered simply by how recently they were introduced.
The field continues to change. In March 2026, the FDA approved teclistamab with subcutaneous daratumumab and hyaluronidase for specified previously treated adults with relapsed or refractory myeloma. A discussion of such an approach must also address infection, reduced immunoglobulins, cytokine release syndrome, neurological toxicity, and the service needed to monitor and manage them. FDA teclistamab combination approval
China's 2025 national guidance on new anticancer medicines includes several myeloma treatments and domestically developed CAR-T products. Each entry has a defined scope, and formulations or previous-treatment requirements can differ. Inclusion does not establish current supply at every hospital or mean the document incorporates every change that occurred during 2026. National Health Commission guidance release
Supportive treatment helps preserve the ability to continue
Bone-directed treatment, pain management, infection prevention, and individualized thrombosis prevention may be needed alongside the regimen. Dental health, kidney function, calcium status, existing bleeding risks, and the proposed drugs can influence these measures. Ask which supportive medicines are essential, how long they continue, and which symptoms should prompt review.
The plan should also specify whom to contact for fever, new weakness, worsening pain, reduced urine output, or a suspected medication reaction. Some problems require local urgent assessment rather than a wait for the next myeloma visit. Family members can help keep the treatment history available, especially when a different hospital must assess an acute event.
Plan care in China around the whole pathway
Provide marrow and FISH results, trends in monoclonal protein and free light chains, kidney function, bone imaging, and the full treatment history before travel. Ask what the receiving team expects an in-person visit to resolve. Fracture risk, dialysis, or recent infection may affect the journey, and a hospital accepting a referral cannot replace the current doctor's travel assessment.
Request separate renminbi estimates for evaluation, induction, collection and transplantation if relevant, maintenance, bone support, and complications. There is no dependable personal total without a defined plan and hospital quotation. Confirm how medicines, laboratory review, and urgent care will continue after returning home so the initial treatment period in China does not end with an unsupported gap.
A useful first consultation leaves you with the immediate treatment goal, the most important problems to report, the first response-assessment point, and an explanation of the next decision. You do not need to master every available drug on the day of diagnosis. Understanding the present task and keeping a clear record will make later choices easier to discuss as the disease and treatment options evolve.